Abstract
Retinoid X receptors (RXRs) occupy a central position within the nuclear receptor superfamily. They not only function as important transcriptional factors but also exhibit diverse nongenomic biological activities. The pleiotropic actions of RXRs under both physiological and pathophysiological conditions confer RXRs important drug targets for the treatment of cancer, and metabolic and neurodegenerative diseases. RXR modulators have been studied for the purpose of developing both drug molecules and chemical tools for biological investigation of RXR. Development of RXR modulators has focused on small molecules targeting the canonical ligand-binding pocket. However, accumulating results have demonstrated that there are other binding mechanisms by which small molecules interact with RXR to act as RXR modulators. This review discusses the recent development in the design and discovery of RXR modulators with a focus on those targeting novel binding sites on RXR.
Keywords: RXRα, tRXRα, Rexinoid, RXRα modulators, Nongenomic action, Nuclear receptors, NSAID, Apoptosis, Inflammation, PI3K
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Recent Progress in the Design and Discovery of RXR Modulators Targeting Alternate Binding Sites of the Receptor
Volume: 17 Issue: 6
Author(s): Ying Su, Zhiping Zeng, Ziwen Chen, Dan Xu, Weidong Zhang and Xiao-kun Zhang
Affiliation:
Keywords: RXRα, tRXRα, Rexinoid, RXRα modulators, Nongenomic action, Nuclear receptors, NSAID, Apoptosis, Inflammation, PI3K
Abstract: Retinoid X receptors (RXRs) occupy a central position within the nuclear receptor superfamily. They not only function as important transcriptional factors but also exhibit diverse nongenomic biological activities. The pleiotropic actions of RXRs under both physiological and pathophysiological conditions confer RXRs important drug targets for the treatment of cancer, and metabolic and neurodegenerative diseases. RXR modulators have been studied for the purpose of developing both drug molecules and chemical tools for biological investigation of RXR. Development of RXR modulators has focused on small molecules targeting the canonical ligand-binding pocket. However, accumulating results have demonstrated that there are other binding mechanisms by which small molecules interact with RXR to act as RXR modulators. This review discusses the recent development in the design and discovery of RXR modulators with a focus on those targeting novel binding sites on RXR.
Export Options
About this article
Cite this article as:
Su Ying, Zeng Zhiping, Chen Ziwen, Xu Dan, Zhang Weidong and Zhang Xiao-kun, Recent Progress in the Design and Discovery of RXR Modulators Targeting Alternate Binding Sites of the Receptor, Current Topics in Medicinal Chemistry 2017; 17 (6) . https://dx.doi.org/10.2174/1568026616666160617092241
DOI https://dx.doi.org/10.2174/1568026616666160617092241 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet Our Regional Editor
Anti-Cancer Agents in Medicinal Chemistry Putative Breast Tumor Suppressor TACC2 Suppresses the Aggressiveness of Breast Cancer Cells through a PLCγ Pathway
Current Signal Transduction Therapy Antiandrogens in Prostate Cancer Endocrine Therapy
Current Cancer Drug Targets Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases
Current Drug Targets Hypoxia Inducible Factor-1 in Cancer Immune Suppression
Current Immunology Reviews (Discontinued) Recent Patents, Formulation Techniques, Classification and Characterization of Liposomes
Recent Patents on Nanotechnology From Test Tube to Clinical Trial; Promising Herbs with NF-κB and COX- 2 Activity
Current Immunology Reviews (Discontinued) Enkephalin-Fentanyl Multifunctional Opioids as Potential Neuroprotectants for Ischemic Stroke Treatment
Current Pharmaceutical Design Vitamin D/VDR, Probiotics, and Gastrointestinal Diseases
Current Medicinal Chemistry Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews Pancreatic Cancer Surgery: The State of the Art
Current Drug Targets Stem Cell Differentiation Stage Factors and their Role in Triggering Symmetry Breaking Processes during Cancer Development: A Quantum Field Theory Model for Reprogramming Cancer Cells to Healthy Phenotypes
Current Medicinal Chemistry Role of Mitochondrial Heat-shock Proteins and Immunophilins in Neuro Degenerative Diseases
Current Drug Targets Primary Management of Metastatic Colorectal Cancer with Bevacizumab. Review Article Focusing on Efficacy
Current Cancer Therapy Reviews Editorial [Hot Topic: ABC Transporters: Role in Modulation of Drug Pharmacokinetics and in Physiopathology and Therapeutic Perspectives (Guest Editor: Francoise Van Bambeke)]
Current Drug Targets Signaling Pathways Responsible for Cancer Cell Invasion as Targets for Cancer Therapy
Current Cancer Drug Targets Vitamin D in Acute Kidney Injury
Inflammation & Allergy - Drug Targets (Discontinued) Ras-Induced Resistance to Lapatinib is Overcome by MEK Inhibition
Current Cancer Drug Targets Combined Therapies of Bone Disease with Bisphosphonates
Current Pharmaceutical Design